KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Receivables (2016 - 2025)

Merck (MRK) has disclosed Receivables for 17 consecutive years, with $11.8 billion as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 14.57% to $11.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $11.8 billion, a 14.57% increase, with the full-year FY2025 number at $11.8 billion, up 14.57% from a year prior.
  • Receivables was $11.8 billion for Q4 2025 at Merck, down from $12.1 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $12.1 billion in Q3 2025 to a low of $8.2 billion in Q1 2021.
  • A 5-year average of $10.6 billion and a median of $10.5 billion in 2022 define the central range for Receivables.
  • Peak YoY movement for Receivables: soared 49.85% in 2021, then decreased 5.07% in 2025.
  • Merck's Receivables stood at $10.2 billion in 2021, then dropped by 2.29% to $10.0 billion in 2022, then increased by 3.9% to $10.3 billion in 2023, then fell by 0.69% to $10.3 billion in 2024, then increased by 14.57% to $11.8 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Receivables are $11.8 billion (Q4 2025), $12.1 billion (Q3 2025), and $11.8 billion (Q2 2025).